The gene for Huntington’s disease “was cloned in 1993, and everyone thought there was going to be a treatment right around the corner,” Sarah Tabrizi told the audience at the 2023 Annual Meeting of the Society for Neuroscience. Then, “it took 25 years for the first trial targeting the Huntington gene.” Read More
Researchers from Wake Forest University, Charles University and affiliated organizations have found a link between mutations in the APOA4 gene and inherited kidney disease. Read More
Takara Bio Inc. has announced the development of a novel adeno-associated virus (AAV) vector, Sonuaav, which exhibits high gene transfer efficiency into inner ear tissues, with a collaborator at Juntendo University School of Medicine. Read More
Researchers from Tscan Therapeutics Inc. presented preclinical data for TSC-200-A0201, a naturally occurring HPV16 E7-specific T-cell receptor (TCR) T-cell therapy discovered using Tscan’s proprietary Receptorscan platform. It is being developed for the treatment of human papillomavirus 16 (HPV16)-positive solid tumors. The therapeutic TCR in TSC-200-A0201 was introduced into a transposon vector, with the resulting TCR T therapy product being a mixture of cytotoxic and helper T cells, both reprogrammed to recognize HPV16+ HLA-A*02:01+ cells. Read More
Blacksmith Medicines Inc. has disclosed glutaminyl-peptide cyclotransferase-like protein (QPCTL; IsoQC) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, psoriasis, chronic obstructive pulmonary disease, atherosclerosis and Alzheimer’s disease, among others. Read More
Ethris GmbH and Heqet Therapeutics srl, a company spun out last year from King’s College London, have entered into a collaboration agreement to harness the potential of non-coding RNA (ncRNA) for heart tissue regeneration following acute myocardial infarction and in heart failure. Read More
Shanghai Sinotau Biotech Co. Ltd. has synthesized tyrosine-protein phosphatase non-receptor type 13 (PTPN13; FAP-1; PTP-1E) inhibitors reported to be useful for the treatment of cancer, inflammation, atherosclerosis, fibrosis and keloid. Read More
Alone or combined with chemotherapy, radiation therapy (RT) is the standard therapeutic option for the majority of non-small-cell lung cancer (NSCLC) cases. Unfortunately, the proportion of patients that experience local-regional relapse can reach 50% of cases. Data from previous investigations link KRAS mutations to radioresistance. Read More
Alchemedicine Inc. has divulged aldehyde dehydrogenase 2 (ALDH2) activators reported to be useful for the treatment of pain, cancer, ischemia-reperfusion injury, nonalcoholic fatty liver disease, peripheral arterial disease, Fanconi anemia, Parkinson’s and Alzheimer’s disease, among others. Read More
Nona Biosciences, a wholly owned subsidiary of HBM Holdings Ltd., has entered into a strategic collaboration with Genequantum Healthcare (Suzhou) Co. Ltd. to advance the early discovery of next-generation bioconjugates. Read More
